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Parkinson’s disease is characterized by the intracellular accumulation of α-synuclein
which has been linked to early dopaminergic axonal degeneration. Identifying druggable
targets that can promote axonal growth in cells overexpressing α-synuclein is important
in order to develop strategies for early intervention. Class-IIa histone deacetylases
(HDACs) have previously emerged as druggable targets, however, it is not known
which specific class-IIa HDACs should be targeted to promote neurite growth in
dopaminergic neurons. To provide insight into this, we used gene co-expression
analysis to identify which, if any, of the class-IIa HDACs had a positive correlation
with markers of dopaminergic neurons in the human substantia nigra. This revealed
that two histone deacetylases, HDAC5 and HDAC9, are co-expressed with TH, GIRK2
and ALDH1A1 in the human SN. We further found that HDAC5 and HDAC9 are
expressed in dopaminergic neurons in the adult mouse substantia nigra. We show
that siRNAs targeting HDAC5 or HDAC9 can promote neurite growth in SH-SY5Y
cells, and that their pharmacological inhibition, using the drug MC1568, promoted
neurite growth in cultured rat dopaminergic neurons. Moreover, MC1568 treatment
upregulated the expression of the neurotrophic factor, BMP2, and its downstream
transcription factor, SMAD1. In addition, MC1568 or siRNAs targeting HDAC5 or
HDAC9 led to an increase in Smad-dependent GFP expression in a reporter assay.
Furthermore, MC1568 treatment of cultured rat dopaminergic neurons increased cellular
levels of phosphorylated Smad1, which was prevented by the BMP receptor inhibitor,
dorsomorphin. Dorsomorphin treatment prevented the neurite growth-promoting effects
of siRNAs targeting HDAC5, as did overexpression of dominant-negative Smad4 or of
the inhibitory Smad7, demonstrating a functional link to BMP signaling. Supplementation
with BMP2 prevented the neurite growth-inhibitory effects of nuclear-restricted HDAC5.
Finally, we report that siRNAs targeting HDAC5 or HDAC9 promoted neurite growth in
cells overexpressing wild-type or A53T-α-synuclein and that MC1568 protected cultured
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 September 2019 | Volume 7 | Article 191
fcell-07-00191 September 12, 2019 Time: 14:55 # 2
Mazzocchi et al. HDAC5/9 and Neurite Growth
rat dopaminergic neurons against the neurotoxin, MPP+. These findings establish
HDAC5 and HDAC9 as novel regulators of BMP-Smad signaling, that additionally may
be therapeutic targets worthy of further exploration in iPSC-derived human DA neurons
and in vivo models of Parkinson’s disease.
Keywords: Parkinson’s, alpha-synuclein, degeneration, histone deacetylase, neurite growth, survival, bone
morphogenetic protein, Smad
INTRODUCTION
Parkinson’s disease (PD) is characterized by the progressive
loss of A9 midbrain dopaminergic (mDA) neurons, and the
accumulation of intracellular aggregates of α-synuclein in Lewy
bodies and Lewy neurites (Spillantini et al., 1997; Lees et al.,
2009). α-synuclein has been linked to PD pathology by studies
showing that SNCA mutations, including the A53T mutation,
cause autosomal dominant PD (Polymeropoulos et al., 1997), and
that α-synuclein is a risk factor for idiopathic PD (International
Parkinson Disease Genomics Consortium, Nalls, 2011). At
the cellular level, multiple studies have linked α-synuclein
accumulation to axonal degeneration in PD (O’Keeffe and
Sullivan, 2018). Specifically, α-synuclein overexpression in
individual mDA neurons reduces neurite growth (Koch et al.,
2015). There is also evidence for alterations in neurite structure
(Oliveira et al., 2015), as well as decreased neurite length
with increased axonal degeneration, in iPSC-derived neurons
carrying an SNCA triplication (Lin et al., 2016) or the A53T
SNCA mutation (Kouroupi et al., 2017). These studies implicate
α-synuclein in mDA neurite degeneration and highlight the
need to identify druggable targets that can prevent axonal
degeneration and/or promote neurite growth in mDA neurons
with an overload of α-synuclein.
Recent work has linked α-synuclein accumulation with
alterations in histone acetylation, a key epigenetic mechanism
that is regulated by histone deacetylases (HDACs) which are
crucial for the correct expression of gene networks that regulate
post-mitotic cell maintenance (Parra, 2015). Accumulation of
wild-type or A53T-α-synuclein has been shown to reduce histone
acetylation and to promote neurotoxicity in mDA neurons
(Kontopoulos et al., 2006). Also, α-synuclein overexpression in
Lund human mesencephalic (LUHMES) cells reduced histone
acetylation, resulting in transcriptional deregulation and DNA
damage, which could be prevented by the pan-HDAC inhibitor,
sodium butyrate (Paiva et al., 2017). This suggests that HDAC
inhibition may be a strategy to promote mDA neurite growth in
cells carrying an α-synuclein overload.
HDACs are divided into a number of different subfamilies
and those belonging to the class-IIa family (HDAC4, HDAC5,
HDAC7, and HDAC9) are unique in that they can shuttle
between the cytoplasm and nucleus (Harrison and Dexter, 2013;
Hegarty et al., 2016b). Recent work has implicated HDAC4 as
a neurotoxic mediator in in vitro and in vivo models of PD
(Wu et al., 2017). Specifically, MPP+ treatment of cultured mDA
neurons obtained from A53T α-synuclein transgenic mice led
to nuclear accumulation of HDAC4, which was neurotoxic (Wu
et al., 2017). In agreement with this, the class-IIa HDAC inhibitor
MC1568 (Mai et al., 2005), was found to promote neurite growth
in mDA neurons, and to protect against the neuritotoxic effects
of MPP+ (Collins et al., 2015). Nuclear export of HDAC5
and HDAC9 has also been shown to be required for axonal
growth in sensory neurons (Cho et al., 2013) and thalamocortical
neurons (Alchini et al., 2017). However, whether class-IIa HDACs
can be targeted to promote neurite growth in cells carrying
α-synuclein, the mechanisms mediating these potential effects,
and the relevance of this to the human midbrain, are unknown.
MATERIALS AND METHODS
Gene Expression Analysis of the Human
SN
Human SN gene expression data from healthy controls
(GSE:60863) (Ramasamy et al., 2014) were analyzed using
the R2: Genomics Analysis and Visualization Platform1.
Pearson correlation analysis with a Bonferroni multiple testing
correction was used to identify which HDACs were significantly
co-expressed with three markers of dopaminergic neurons,
ALDH1A1, GIRK2, and TH, and then subsequently to identify
all genes that were significantly co-expressed with HDAC5
and HDAC9. All gene expression data are presented as log2
expression values.
Cell Culture
SH-SY5Y cells, a widely used cell line model of human DA
neurons (Xicoy et al., 2017), were used. These cells were
maintained in Dulbecco’s Modified Eagle Medium Nutrient
Mixture F-12 (Sigma), supplemented with 10% fetal bovine
serum (Sigma), 100 nM L-Glutamine (Sigma), 100 U/ml
Penicillin (Sigma), 10 µg/ml Streptomycin (Sigma), in a
humidified atmosphere containing 5% CO2 at 37◦C. Primary
cultures of embryonic (E) day 14 rat ventral midbrain
(VM) (from the Biological Service Unit, University College
Cork) were dissected as described (Hegarty et al., 2016a).
All scientific procedures were performed under a license in
accordance with the European Communities Council Directive
(86/609/EEC) and approval by local Animal Experimentation
Ethics Committee. After dissection, tissue was dissociated
and neurons were plated in poly-D-lysine coated 24-well
plates (Sigma) in DMEM:F12 media (Sigma) supplemented
with 1% penicillin/streptomycin (Sigma), 1% L-glutamine
(Sigma), 2% B27 (Invitrogen) and 1% FBS. Where indicated,
cells were pre-treated for 30 min with 1 µg/ml of the
1https://hgserver1.amc.nl/cgi-bin/r2/main.cgi
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BMPR1 inhibitor, dorsomorphin (Sigma). Recombinant human
BMP2 was added at a final concentration of 50 ng/ml
(Gibco) as in previous studies (Goulding et al., 2019). The
class-IIa HDAC inhibitor MC1568 (Sigma) was added at
concentrations ranging from 0.01–0.1 µM, as indicated in the
figure legends.
Plasmids and siRNA
1.5 × 105 cells per well were transfected using TransIT-
X2 Dynamic Delivery System (Mirus) according to the
manufacturer’s instructions with various combinations of
the following plasmids or siRNAs as indicated in the relevant
figure legends: EGFP-alpha-synuclein-WT (Addgene plasmid
# 408222; RRID:Addgene_40822) and EGFP-alphasynuclein-
A53T (Addgene plasmid #408233; RRID:Addgene_40823)
were a gift from David Rubinsztein (Furlong et al., 2000);
pCMV5 DPC4 (1-514) (Smad4 dominant negative; Addgene
plasmid #140404; RRID:Addgene_14040) was a gift from
Joan Massague (Lagna et al., 1996). pcDNA3-Smad7 was a
gift from Aristidis Moustakas (Addgene plasmid #808935;
RRID:Addgene_80893); GFP Cignal reporter (Qiagen CCS-
017G); HDAC5 wild-type (WT) (Addgene plasmid #322136;
RRID:Addgene_32213) and HDAC5 S259A/S498A (Addgene
plasmid #322167; RRID:Addgene_32216) were gifts from Reuben
Shaw (Mihaylova et al., 2011). For siRNA experiments, cells were
transfected with 25 nM of commercially available Silencer R© pre-
designed siRNAs targeting HDAC4, HDAC5, HDAC7, HDAC9 or
scrambled control siRNA (ThermoFisher).
Quantitative Real-Time PCR (RT-qPCR)
The levels of Hdac5 and Hdac9 mRNAs in postnatal
day (P)5 and adult (P90) VM were quantified by RT-
qPCR relative to a geometric mean of mRNAs for the
housekeeping enzymes glyceraldehyde phosphate dehydrogenase
(Gapdh), succinate dehydrogenase (Sdha) and hypoxanthine
phosphoribosyltransferase-1 (Hprt1) as previously described
(Hegarty et al., 2017). Briefly, 5 µl of total midbrain RNA was
reverse transcribed for 1 h at 45◦C using the AffinityScript
kit (Agilent, Berkshire, United Kingdom) in a 25 µl reaction
according to the manufacturer’s instructions. 2 µl of cDNA
was amplified in a 20 µl reaction volume using Brilliant III
ultrafast qPCR master mix reagents (Agilent Technologies)
with 150 nM of primers and 300 nM of dual-labeled
(FAM/BHQ1) hybridization probes specific to each of the
cDNAs (MWG/Eurofins, Ebersberg, Germany) using the
Mx3000P platform (Agilent). The PCR primers were: Hdac5
forward: 5′-TCC CTC CTA CAA ATT GCC-3′ and reverse:
5′-GGT GAT CTC AAC TGC TCT C-3′; Hdac9 forward: 5′-CGT
CTC CAT CCT ACA AGT A-3′ and reverse: 5′-CTC CTC TCT







CCC TAT GAC AGC CGT GAT GAC T BHQ1-3′; Hdac9
5′-FAM TAA CCT GGA CCG CAC CTT CAA BHQ1-3′. To
determine whether class-IIa HDAC inhibition regulates the
expression of mRNAs encoding BMP2 and components of the
BMP signaling pathway, total RNA from SH-SY5Y cells that had
been cultured for 12 h either with or without 0.1 µM MC1568
was reverse transcribed and the resulting cDNA amplified by
qPCR, as described above, with primers and dual-labeled probes
targeting either BMP2, SMAD1, SMAD5, BMPR2, ACVR2A or
BMPR1B. Target mRNA levels were expressed relative to the
geometric mean of the reference mRNAs, GAPDH, Tata binding
protein (TBP) and β2-microglobulin (B2M). The primers were:
BMP2 forward: 5′-GGA GAT TCT TCT TTA ATT TAA G-3′ and
reverse: 5′-ACT GCT ATT GTT TCC TAA-3′; SMAD1 forward:
5′-CCA CTA TAA GAG AGT AGA AAG-3′ and reverse: 5′-CTG
GAA AGA ATC TGG AAA-3′; SMAD5 forward: 5′-ATG CCC
AGT ATA TCC AGC-3′ and reverse: 5′-GAA GGA TCT GTG
AAT CCA TC-3′; BMPR2 forward: 5′-TGG GAA AGA AAC
AAA TCT G-3′ and reverse: 5′-TGA GGA GGA AGA ATA ATC
TG-3′; ACVR2A forward: 5′-CCA GCA TCC ATC TCT TGA-3′
and reverse: 5′-GTC GTG ATC CCA ACA TTC-3′; BMPR1B
forward: 5′-CAC AGA AAG GAA CGA ATG-3′ and reverse:
5′-AGA GCA AAC TAC AGA CAG-3′; GAPDH forward:
5′-TGG TCT CCT CTG ACT TCA-3′ and reverse: 5′-GCT GTA
GCC AAA TTC GTT G-3′; TBP forward: 5′-CTC ACA GAC
TCT CAC AAC-3′ and reverse: 5′-AGG TCA AGT TTA CAA
CCA A-3′; B2M forward: 5′-CCT GAA TTG CTA TGT GTC-3′
and reverse: 5′-CAG TGT AGT ACA AGA GAT AGA-3′. Dual
labeled probes were: BMP2 5′-FAM-CCC ACG GAG GAG TTT
ATC ACC-BHQ1-3′; SMAD1 5′-FAM-ACT TCC TCC TGT
GCT GGT TCC-BHQ1-3′; SMAD5 5′-FAM-AGC CTG TTG
CCT ATG AAG AGC C-BHQ1-3′; BMPR2 5′-FAM-TCA ATC
CAA TGT CTA CTG CTA TGC-BHQ1-3′; ACVR2A 5′-FAM-
ACA GAG CAT TGC CAT TCC AGC-BHQ1-3′; BMPR1B
5′-FAM-ACC TAC ACC CTA CAC TGC CTC-BHQ1-3′.
End Point PCR
For end point PCR, two million cells per experimental condition
were plated on a 6-well plate. Total RNA was isolated using
the RNeasy Plus Universal Mini Kit (QIAGEN R©) according
to manufacturer’s indications. DNase I treatment was included
to ensure complete removal of gDNA. RNA concentration
was measured using a Thermo ScientificTM NanoDropTM
spectrophotometer. RNA integrity was verified by electrophoresis
in a bleach agarose gel. cDNA was synthetized from 1 µg of
total RNA using the LunaScriptTM RT SuperMix (New England
Biolabs R© Inc.). Endpoint PCR was carried on a SureCycler 8800
Thermal Cycler (Agilent Technologies, Inc.) using OneTaq R© Hot
Start Quick-Load R© (New England Biolabs R© Inc.) in a final volume
of 20 µL. The PCR primers were: HDAC4 forward: 5′-GAC CCA
ATG CAA ACG CTG TCC GTT CC-3′ and reverse 5′-GGT GAC
CGT CTC GGC TTC TTC GTT CTC-3′. HDAC5 forward: 5′-
GGC AAT GGC ACC CAG CAG GCG TTC TAC-3′ and reverse:
5′-CCA CAC CTC CTG TCC ATG CCA CGT TCA C-3′. HDAC7
forward: 5′-CCG CTC AGC CGC CTC AAA CTG GAC AAC-
3′ and HDAC7 reverse: 5′-CCC AGC GGG CTG CAT TGG
AGG AAT GA-3′. HDAC9 forward: 5′-CGC AGT GCC ATC
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CCA GCT CAA TGC TTC G-3′ and reverse 5′-CCT GGT GGC
TGC TGT TGG GTG GCT TTC-3′. Fifty nanograms of cDNA
template were amplified for 40 cycles (95◦C, 15 s + 70◦C, 30 s)
followed by a final extension step at 70◦C for 5 min. After PCR,
amplicons generated were loaded on a 1.8% agarose 1% TAE
gel. Electrophoresis was run at 80 V for 45 min and bands were
visualized on a UV transilluminator.
Immunocytochemistry
Cultures were fixed for 15 min using 4% paraformaldehyde.
Following 3 × 5 min washes in 10 mM PBS-T (0.02%
Triton X-100 in 10 mM PBS), cultures were incubated in
5% bovine serum albumin (BSA) in 10 mM PBS-T for 1 h
at room temperature. Cultures were subsequently incubated
in the following primary antibodies: tyrosine hydroxylase
(TH) (Millipore ab152; 1:200), α-synuclein (Millipore 36/008;
1:2000), Smad1/5/9 (Abcam ab66737 1:200) or phospho-Smad
1/5/9 (Cell Signaling 13820S 1:200), diluted in 1% BSA in
10 mM PBS at 4◦C overnight. Following 3 × 5 min washes
in 10 mM PBS-T, cells were incubated in 594-conjugated
secondary antibodies (Invitrogen; 1:500 A11005 or A11012)
in 1% BSA prior to 3 × 5 min washes and counterstained
with DAPI (1:3000, Sigma). Cells were imaged using an
Olympus IX71 inverted microscope. The fluorescence intensity
of individual cells was measured by densitometry using Image J
analysis software.
Immunohistochemistry
Eight-week-old C57BL/6J male mice were transcardially perfused
with 4% paraformaldehyde and brains were fixed overnight
in 4% paraformaldehyde followed by cryoprotection in 30%
sucrose. Fifty-micrometre-thick serial frozen sections were
cut and processed for immunohistochemistry using primary
antibodies for HDAC5 (Abcam ab55403; 1:200), HDAC9
(Abcam ab59718; 1:250) and TH (Millipore ab152; 1:1000 or
Abcam ab76442; 1:1000) and DAPI (1:3000). Primary antibody
binding was detected using the following secondary antibodies:
AlexaFluor 594 (Life Tech A11012; 1:1000) and AlexaFluor
488 (Life Tech A11039; 1:2000). Sections were imaged using a
confocal microscope.
Neurite Growth and Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6
(©2018 GraphPad Software, CA, United States). All experiments
were performed in triplicate and were repeated at least three
times. For analysis of neurite growth, five non-overlapping
images were captured from each well in each experimental group.
The measurement of neurite length was carried out using the
trace function in Image J. For neurite growth measurements,
≥135 cells from at least three experiments were analyzed.
All data are presented as mean ± SEM of the number of
experimental replicates rather than of the number of cells.
Statistical differences were analyzed using a Student’s t-test
or one-way ANOVA as appropriate with the post hoc test as
indicated in the figure legends.
RESULTS
Co-expression Analysis of Human and
Mouse SN Identifies HDAC5 and HDAC9
Co-expression With Multiple Markers of
Midbrain Dopaminergic Neurons
We first investigated whether any class-IIa HDACs (HDAC4,
5, 7, and 9) were co-expressed with multiple markers of mDA
neurons in the human SN. The rationale for this approach is
that correlated patterns of gene expression can reflect a co-
expression and/or a functional association (Eisen et al., 1998;
Homouz and Kudlicki, 2013). To investigate this, we used
available gene expression data (GSE: 60863) from the human SN
(Ramasamy et al., 2014), and identified from among all genes,
those class-IIa HDACs that had a significant positive correlation
with the expression of three markers of mDA neurons: TH,
GIRK2/KCNJ6, and ALDH1A1. Of the class-IIa HDACs, HDAC5
(Figure 1A) and HDAC9 (Figure 1B), but not HDAC4 and
HDAC7, were found to have a significant positive correlation
with all three mDA markers. These data show that transcripts
for HDAC5 and HDAC9 display a positive co-expression pattern
with transcripts for multiple markers of mDA neurons in the
human SN, suggesting that they may play a functional role in
mDA neurons. To gain some insight into this possible role,
we next identified all genes that had a significant positive
correlation with transcripts for HDAC5 and HDAC9 (Figure 1C).
A gene ontology (GO) analysis revealed that the GO category
“Neurofilament cytoskeletal organization” (Figure 1D) was the
top hit, suggesting that these HDACs may regulate neurite growth
and or neurite maintenance.
To confirm these findings on HDAC5 and HDAC9 expression
in the human SN, we next used quantitative real-time PCR
(RT-qPCR) to measure the levels of Hdac5 and Hdac9 mRNAs
in mouse VM at P5 and in adulthood (P90). Both Hdac5
(Figure 2A) and Hdac9 (Figure 2B) were expressed at P5 and
in adulthood. Immunohistochemistry confirmed the expression
of HDAC5 (Figures 2C,D) and HDAC9 (Figures 2C,E), both
of which were predominantly localized to the cytoplasm of
almost all TH-positive mDA neurons in adult mouse SNpc
(95.34 ± 1.54% for HDAC5 and 93.95 ± 2.11% for HDAC9)
(Figure 2C). These data show that HDAC5 and HDAC9 are
expressed by mDA neurons in the adult mouse SN.
siRNAs Targeting HDAC5 or HDAC9, but
Not HDAC4 or HDAC7, or
Pharmacological Class-IIa Inhibition
Promotes Neurite Growth in SH-SY5Y
Cells and in Cultured Neurons From E14
Rat VM
To study the function of these HDACs, human SH-SY5Y
cells were first used as these express all four class-IIa HDACs
(Figure 3A and Supplementary Figures 1A,B) and as they
are often used as a cell line model of human DA neurons for
initial functional characterization of new molecular targets albeit
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FIGURE 1 | Gene co-expression analysis of HDAC5 and HDAC9 in the human substantia nigra. (A,B) Graphs showing the correlation between (A) HDAC5 and
(B) HDAC9 and three markers of midbrain dopaminergic neurons (TH, GIRK2/KCNJ6, ALDH1A1) in the human substantia nigra (n = 101). The r and
Bonferroni-corrected p-values shown on each graph. Raw data were derived from data set GSE60863 and analyzed using the R2 microarray platform. (C) Venn
diagram showing the number of genes in the human substantia nigra displaying a multiple testing adjusted correlation of ≥0.6 with HDAC5 (n = 1303) and HDAC9
(n = 2361), and the overlap between them (n = 651) in the SN. (D) Table showing a gene ontology (GO) enrichment analysis of these gene lists. The top category
associated with each gene list is shown, along with the fold-enrichment and FDR adjusted p value.
with some limitations (Xicoy et al., 2017). Given the gene co-
expression analysis results (Figures 1C,D), neurite growth was
used as a functional readout which allowed the effects of HDAC
knockdown in individual cells to be examined. To do this, SH-
SY5Y cells were transfected with a plasmid expressing GFP
to identify transfected cells, together with 25 nM of either a
scrambled siRNA, or siRNAs against HDAC5, HDAC9, HDAC4,
or HDAC7. Quantification of neurite growth in GFP-expressing
cells revealed that only siRNAs against HDAC5 or HDAC9 led to
significant increases in neurite growth which were progressively
greater over time at 24, 48 and 72 h (Figures 3B,C). Densitometry
confirmed that these siRNAs reduced HDAC protein levels
(Supplementary Figure 2). In support of these findings, we also
transfected SH-SY5Y cells with either a control plasmid, or a
plasmid expressing either wild-type HDAC5 or a HDAC5 mutant
that is retained in the nucleus (HDAC5-S259A/S498A), where it
maintains deacetylase activity (Cho et al., 2013; Figure 3D). Cells
expressing nuclear-restricted HDAC5 had significantly lower
levels of acetylated histone 3 (AcH3)-K9.K14 (Figure 3E) and
of neurite growth (Figures 3F,G) compared to controls. These
data indicate that neurite growth in SH-SY5Y cells is negatively
regulated by class-IIa HDAC5 or HDAC9, and that cytosolic
export of HDAC5 is required to prevent this process.
To provide support for these findings, we also used the
class-IIa pharmacological inhibitor MC1568, which inhibits both
HDAC5 and HDAC9 (Mai et al., 2005). SH-SY5Y cells were
treated for 72 h with 0.01 or 0.1 µM of MC1568. Quantification
of the levels of AcH3-K9.K14 (as a readout of HDAC inhibition)
showed a significant increase in histone acetylation after MC1568
treatment (Figure 4A). Similar to the effects of HDAC5 and
HDAC9 inhibition, treatment with MC1568 also led to an
increase in neurite growth (Figure 4B), without any adverse
effects on cell survival, as measured using an LDH assay
(Figure 4C). To confirm the relevance of these findings in
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FIGURE 2 | HDAC5 and HDAC9 transcripts and protein are expressed in dopaminergic neurons in mouse substantia nigra. (A,B) RT-qPCR showing the expression
of transcripts for (A) Hdac5 and (B) Hdac9 in mouse midbrain at postnatal day (P)5 and P90 relative to the levels of the geometric mean of three reference mRNAs,
Gapdh, Sdha, and Hprt1. Data are mean ± SEM from n = 3–6 mice at each time point. ∗∗P < 0.01, Student’s t-test. (C) Quantification of TH-immunopositive
neurons in the SN that express HDAC5 or HDAC9. (D,E) Immunohistochemistry showing (D) HDAC5 (red) and (E) HDAC9 (red) expression in TH-positive neurons
(green; arrow), colabelled with DAPI (blue), in adult mouse substantia nigra. Scale bar = 50 µm. Data are mean ± SD from n = 3 mice.
cultured DA neurons, we treated primary cultures of E14 rat
VM with 0.01 µM of MC1568 for 24 h. Again we found an
increase in AcH3 (Figure 4D), and also an increase in neurite
length in DA neurons in these cultures (Figures 4E,F). To
confirm that a similar increase was also seen with the siRNA, we
transfected primary cultures of E14 rat VM with siRNAs against
Hdac5 or Hdac9 or a scrambled control. In agreement with
the SH-SY5Y data, siRNAs targeting Hdac5 or Hdac9 increased
neurite growth in cultured neurons (siSCR = 217.3 ± 9.8 µm vs.
siHDAC9 = 293.1 ± 3.7 µm and siHDAC9 = 260 ± 16.4 µm)
(Figures 4G,H).
Bioinformatics Analysis Links HDAC5/9
to the Bone Morphogenetic Protein
Pathway
To gain insights into the molecular mechanisms that underlie
the neurite growth-promoting effects of HDAC5 and HDAC9
knockdown, we first analyzed gene expression data from
a previously published microarray study that profiled gene
expression in primary cultures of E14 mouse VM after
treatment with the pan-HDIs trichostatin A, valproic acid
or sodium butyrate for 48 h (Forgione and Tropepe, 2012).
This analysis identified 127 genes that were significantly
upregulated by all three HDIs (Forgione and Tropepe, 2012).
We performed a gene ontology (GO) enrichment analysis8
which revealed a statistically significant overrepresentation of
8http://geneontology.org/
genes associated with GO categories related to multiple aspects
of axon development (data not shown), and to the bone
morphogenetic protein (BMP) signaling pathway (12.44-fold
enrichment; adj. p = 0.0127).
We next examined data from a previous report that
performed an unbiased analysis of HDAC5 genomic binding
sites using ChIP-seq in mouse striatal neurons (Taniguchi
et al., 2017). We performed a KEGG pathway analysis of
HDAC5-associated target genes which revealed a significant
enrichment of genes associated with the ‘TGF-beta signaling
pathway’ (KEGG ID: 04350; adj. p = 6.67 × 10−05). Among
the list of genes associated with this pathway was BMP2,
which is a neurotrophic factor for mDA neurons (Goulding
et al., 2019). Collectively, these data suggest that HDAC5
and HDAC9 inhibition may regulate BMP2 expression
and/or BMP signaling.
Selective Class-IIa Inhibition Increases
BMP Signaling in SH-SY5Y Cells and in
Cultured DA Neurons From E14 Rat VM
To test this, SH-SY5Y cells were treated for 12 h with 0.1 µM
of the class-IIa pharmacological inhibitor MC1568 (Mai et al.,
2005). The expression of BMP2 and multiple components
of the BMP pathway, including the BMP receptors (BMPR2,
ACVR2A and BMPR1B) and of the R-Smads transcription
factors (SMAD1 and SMAD5) was examined by RT-qPCR
(Figure 5A). A pharmacological approach was used rather than
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FIGURE 3 | siRNAs targeting HDAC5 or HDAC9, but not other class-IIa HDAC family members HDAC4 or HDAC7, promote neurite growth in SH-SY5Y cells.
(A) Representative photomicrographs of SH-SY5Y cells immunocytochemically stained for HDAC5 (red) or HDAC9 (red) with DAPI (blue). Scale bar = 10 µm.
(B) Representative photomicrographs of SH-SY5Y cells and (C) graph of neurite length at 24, 48, and 72 h post-transfection with 25 nM of a scrambled siRNA
(siSCR) or siRNAs against the four class-IIa HDACs (siHDAC4, siHDAC5, siHDAC7, siHDAC9). Scale bar = 50 µm. Data are mean ± SEM as percentage of the
siSCR control of n = 3 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. siSCR group; two-way ANOVA with post hoc Tukey’s test.
(D) Immunocytochemistry showing nuclear localization of mutant HDAC5-S259A/S498A which is retained in the nucleus. Graphs of (E) AcH3-K9.K14 levels and
(F,G) neurite length of SH-SH5Y cells at 72 h post-transfection with a control plasmid (GFP) or plasmids expressing wild-type (WT) HDAC5 or mutant
HDAC5-S259A/S498A. Scale bar = 100 µm. Data are presented as the mean ± SEM as a percentage of the GFP control of n = 3 independent experiments.
∗p < 0.05 vs. Control; one-way ANOVA with post hoc Fishers LSD test.
siRNA due to the low transfection efficiency of SH-SY5Y cells
(∼25%). MC1568 treatment led to a significant increase in
the expression of transcripts for BMP2 and its transcription
factor SMAD1, without affecting the expression of other
components of the BMP-Smad pathway (Figures 5B–G). To
provide further evidence that MC1568 treatment modulates
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FIGURE 4 | Beneficial effects of pharmacological or siRNA-mediated inhibition of HDAC5 or HDAC9 in SH-SY5Y cells and dopamine neurons in E14 rat VM primary
cultures. Graphs showing (A) the relative levels of acetylated histone 3 (Ach3), (B) neurite length and (C) lactate dehydrogenase (LDH) levels as a measure of cell
viability in SH-SY5Y cells treated with 0.01 or 0.1 µM MC1568 for 72 h. (D,E) Graphs showing (D) the relative levels of acetylated histone 3 (Ach3) and (E,F) neurite
length in TH-positive neurons in primary cultures of E14 rat VM treated with 0.01 µM MC1568 for 24 h. (G) Graph showing neurite length and (H) representative
photomicrographs of primary cultures of E14 rat VM at 24 h post-transfection with 25 nM of a scrambled siRNA (siSCR) or siRNAs against HDAC5 (siHDAC5) or
HDAC9 (siHDAC9). Scale bar = 50 µm. Insert are tracing of individual neurons in the image. Data are mean ± SEM of n = 3 independent experiments. ∗p < 0.05,
∗∗p < 0.01 vs. siSCR group; Student’s t-test or one-way ANOVA with post hoc Fishers LSD test.
BMP signaling, we next analyzed BMP-dependent transcription.
To do this, SH-SY5Y cells were transfected with a Smad-
GFP reporter construct in which GFP expression is under
the control of a Smad-responsive minimal promoter, and
were co-transfected with either a scrambled siRNA, or
siRNAs against HDAC5 or HDAC9, or were treated with
MC1568. The level of GFP fluorescence was quantified at
72 h, revealing that siRNAs against HDAC5 or HDAC9, or
treatment with MC1568, led to significant increases in GFP
expression, indicating a Smad-dependent transcriptional
response (Figures 5H,I).
To confirm the relevance of this for cultured DA neurons,
we treated cultures of E14 rat VM with MC1568 with or
without dorsomorphin, a small molecule that blocks BMP
signaling (Yu et al., 2008), and quantified the levels of
pSmad1/5/8 in TH-positive neurons in these cultures. This
analysis revealed that MC1568 treatment lead to a significant
increase in the levels of pSmad1/5/8 in DA neurons, which
was blocked by dorsomorphin (Figure 5J). Collectively, these
data suggest that the BMP-Smad signaling pathway may
mediate the neurite growth-promoting effects of HDAC5 and
HDAC9 inhibition.
HDAC5 siRNA or MC1568 Promotes
Neurite Growth Through the BMP-Smad
Signaling Pathway
We next tested the hypothesis that the BMP-Smad signaling
pathway may mediate the neurite growth-promoting effects of
HDAC5 inhibition. To do this, SH-SY5Y cells were transfected
with a GFP expression plasmid together with 25 nM of either
a control siRNA or siRNAs against HDAC5, and cultured
for 24 h with or without dorsomorphin. Transfection with
HDAC5 siRNA led to a significant increase in neurite growth
compared to the scrambled control (siSCR), which was not
seen when siHDAC5 cells were also treated with dorsomorphin
(siSCR = 49.74 ± 1.37 µm vs. siHDAC5 = 76.40 ± 1.82 µm vs,
siHDAC5+ dorsomorphin = 44.05± 1.39 µm) (Figures 6A,B).
To further confirm the potential involvement of the BMP-
Smad pathway, we transfected SH-SY5Y cells with 25 nM of
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FIGURE 5 | Class-IIa HDAC inhibition increases BMP2 and SMAD1 expression in SH-SY5Y cells. (A) Schema of the BMP pathway. (B–G) RT-qPCR data showing
(B) BMP2, (C) BMPR2, (D) ACVR2A, (E) BMPR1B, (F) SMAD1 and (G) SMAD5 mRNA levels relative to the levels of the geometric mean of three reference mRNAs,
GAPDH, TBP and B2M, in SH-SY5Y cells treated for 12 h with 0.1 µM of the class-IIa HDAC inhibitor MC1568. Data are mean ± SEM from n = 4 independent
experiments expressed as fold change relative to the control. (H) Graph and (I) representative photomicrographs showing the expression of GFP (as a readout of
Smad-dependent transcription) in SH-SY5Y cells transfected with a Smad-GFP reporter construct and co-transfected with either a scrambled siRNA, or siRNAs
against HDAC5 or HDAC9 or treated with MC1568 for 72 h. (J) Graph showing the relative levels of pSmad1/5/8 in TH-positive neurons in primary cultures of E14
rat VM at 24 h post-treatment with 0.01 µM MC1568. Scale bar = 50 µm. Data are mean ± SEM from n = 3 independent experiments expressed as fold change
relative to the control. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. Control; Student’s t-test or one-way ANOVA with post hoc Tukey’s test as appropriate).
either a control siRNA or HDAC5 siRNA, and co-transfected
them with either a control plasmid or a plasmid expressing the
inhibitory SMAD7 (Figure 6C) or dominant-negative SMAD4
(SMAD4dn) (Figures 6D,E). Transfection with HDAC5 siRNA
led to a significant increase in neurite growth compared to the
scrambled control, which was not seen when co-transfected with
expression plasmids for SMAD7 or SMAD4dn (Figures 6C–E).
To confirm the relevance of this for cultured DA neurons, we
treated primary cultures of E14 rat VM with MC1568 with
or without dorsomorphin for 24 h. We found that treatment
with MC1568 led to a significant increase in neurite growth
of DA neurons, that was prevented by co-treatment with
dorsomorphin (Figure 6F).
We next performed a rescue experiment to determine
if supplementation with BMP2 could rescue the reduction
in neurite growth seen in cells expressing nuclear-restricted
HDAC5. To do this, SH-SY5Y cells were transfected with the
plasmid expressing HDAC5-S259A/S498A and cultured with or
without 50 ng/ml BMP2 for 24 h. Quantification of neurite
growth revealed a significant decrease in HDAC5-S259A/S498A-
expressing cells compared to controls (100% vs. 69.75 ± 2.62%;
p < 0.01) (Figure 6G). In contrast, we found that BMP2
treatment of HDAC5-S259A/S498A-expressing cells normalized
neurite growth to control levels (100% vs. 111.70 ± 4.35%; not
significant) (Figure 6G). Collectively, these data show that the
BMP-Smad signaling pathway mediates the growth-promoting
effects of HDAC5 inhibition.
HDAC5 and HDAC9 siRNA Promotes
Neurite Growth in Cells Overexpressing
Wild-Type or A53T α-Synuclein and in
Cultured DA Neurons Treated With MPP+
At the cellular level, a pathological hallmark of PD is the
accumulation of intracellular α-synuclein. Therefore, we next
examined whether inhibition of class-IIa HDACs could promote
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FIGURE 6 | The neurite growth-promoting effects of HDAC5 inhibition require BMP-Smad signaling. (A–E) In all experiments cells were transfected with 25 nM of a
scrambled siRNA (siSCR) or siRNAs against HDAC5 (siHDAC5) and neurite length was analyzed at 24 h. (A) Quantification of neurite length per cell (B)
representative photomicrographs when co-treated with 1 µg/ml of the BMPR1 inhibitor, dorsomorphin. Neurites are indicated by white arrows. Scale bar = 50 µm.
(C,D) Quantification of neurite length per cell and (E) representative photomicrographs of cells co-transfected with plasmids overexpressing (C) the inhibitory
I-Smad, Smad7 or (D,E) Smad4 dominant negative (Smad4dn). (F) Graph showing the neurite length of TH-positive neurons in primary cultures of E14 rat VM at
24 h post-treatment with 0.01 µM MC1568. (G) A rescue experiment in which the cells were transfected with the nuclear-restricted HDAC5 mutant and cultured
with or without 50 ng/ml BMP2. Data mean ± SEM as a percentage of the control of n = 3–4 independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.01 vs.
siSCR group alone; one-way ANOVA with post hoc Tukey’s test.
neurite growth in cells overexpressing wild-type (WT) or
A53T-α-synuclein. SH-SY5Y cells were transfected with either
a control-GFP plasmid, or a plasmid expressing either GFP-
tagged WT (αSynWT-GFP) or A53T α-synuclein (αSynA53T-
GFP) (Figures 7A,B). Cultures were also co-transfected with
siRNA against each of the four class-IIa HDACs and then
cultured for 72 h. Quantification of the neurite lengths of
transfected cells revealed that overexpression of WT-α-synuclein
resulted in a significant decrease in neurite length when
compared to controls (23.76 ± 0.92 µm vs. 35.58 ± 0.92 µm;
p < 0.001) (Figure 7C). Co-transfection of WT-α-synuclein-
overexpressing cells with siRNAs against HDAC5 or HDAC9,
led to significant increases in neurite growth compared to the
groups with the scrambled siRNA and the control plasmid,
and also to the groups with the scrambled siRNA plus
WT-α-synuclein (siSCR + WT-α-synuclein = 23.76 ± 0.92 µm
vs. siHDAC5 + WT-α-synuclein = 53.73 ± 1.35 µm or
siHDAC9 + WT-α-synuclein = 42.05 ± 1.17 µm; p < 0.001)
(Figure 7C). Transfection with siRNAs against HDAC4 and
HDAC7 did not affect neurite growth in cells expressing WT-
α-synuclein (Figure 7C).
Similarly, overexpression of A53T-α-synuclein also resulted
in a significant decrease in neurite length when compared to
controls (17.46 ± 0.89 µm vs. 31.40 ± 0.09 µm; p < 0.001)
(Figure 7D). siRNAs against HDAC5 and HDAC9, but not
HDAC4 and HDAC7, also led to significant increases in
neurite growth compared to the group transfected with the
scrambled siRNA or the control plasmid, and compared
to the group transfected with the scrambled siRNA plus
WT-α-synuclein (siSCR+ A53T-α-synuclein = 17.46± 0.89 µm
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FIGURE 7 | Beneficial effects of pharmacological or siRNA-mediated inhibition of HDAC5 or HDAC9 in cells overexpressing wild-type or A53T α-synuclein, or treated
with MPP+. (A,B) Representative photomicrographs of SH-SY5Y cells transfected with (A) GFP or (B) an expression plasmid expressing GFP-tagged wild-type
α-synuclein (αSynWT-GFP) and immunocytochemically stained for α-synuclein (red). (C,D) Graphs of neurite length of SH-SY5Y cells at 72 h post-transfection with
25 nM of a scrambled siRNA (siSCR) or siRNAs against the four class-IIa HDACs (siHDAC4, siHDAC5, siHDAC7, siHDAC9) and co-transfected with a GFP control
plasmid or a plasmid expressing (C) αSynWT-GFP or (D) αSynA53T-GFP. Data are presented as the mean ± SEM as a percentage of the GFP control of n = 3
independent experiments. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. Control; ###p < 0.001 vs. siSCR plus WT or A53T α-synuclein: One-way ANOVA with Tukey’s
post hoc test. (E) Graphs of neurite length of TH-positive neurons in primary cultures of E14 rat VM at 24 h post-treatment with 1 mM MPP+ with or without
0.01 µM of MC1568. Data are presented as mean ± SEM as a percentage of the control of n = 3 independent experiments. ∗∗p < 0.01, vs. Control; One-way
ANOVA with Fishers LSD post hoc test.
vs. siHDAC5 + A53T-α-synuclein = 39.54 ± 1.37 µm or
siHDAC9 + WT-α-synuclein = 35.72 ± 1.49 µm; p < 0.001)
(Figure 7D). Collectively, these data show that siRNAs targeting
HDAC5 or HDAC9 can promote neurite growth in cells
overexpressing WT- or A53T-α-synuclein.
We next sought to confirm the relevance of this for cultured
DA neurons. Given the difficulties in transfecting sufficient
amounts of DA neurons, we treated primary cultures of E14
rat VM with the neurotoxin MPP+ and cultured them for
24 h with or without 0.01 µM MC1568. Treatment with MPP+
lead to a significant decrease in the neurite length of TH-
positive neurons that was not seen in cultures co-treated with
MC1568 (Figure 7E). Collectively, these data suggest that class-
IIa HDAC inhibition, likely through inhibition of HDAC5 and
HDAC9, can protect cells against α-synuclein- and MPP+-
induced degeneration.
DISCUSSION
Gene co-expression analysis is a recently developed approach
for the analysis of cellular functional organization by identifying
coordinated patterns of co-expressed genes (van Dam et al.,
2018). In the present study we have used gene-co-expression
analysis of the human SN to show a significant correlation
between HDAC5 and HDAC9 and multiple markers of human
dopaminergic neurons. We confirmed the gene co-expression
pattern by showing that HDAC5 and HDAC9 were expressed in
dopaminergic neurons in the adult mouse SN.
We next transfected SH-SY5Y cells with siRNAs targeting each
member of the class-IIa HDAC family. We found that siRNAs
targeting HDAC5 and HDAC9, but not HDAC4 and HDAC7,
led to a significant increase in neurite growth. This is consistent
with a previous report showing that the class-IIa HDAC inhibitor
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MC1568 promotes dopaminergic and sympathetic axon growth
(Collins et al., 2015). Our current findings show that the positive
effects of class-IIa HDAC inhibition on axon growth are mediated
through the inhibition of HDAC5 and HDAC9, rather than of
HDAC4 and HDAC7. We further found that overexpression of
nuclear-restricted HDAC5, but not of wild-type HDAC5, led to
a significant decrease in neurite growth. These findings are fully
consistent with previous reports showing that axon injury in
peripheral sensory neurons resulted in nuclear export of HDAC5,
which promoted axon regeneration both in vitro and in vivo (Cho
et al., 2013). Moreover, previous studies have implicated HDAC9
as a negative regulator of reinnervation of mouse skeletal muscle
(Macpherson et al., 2015), and shown that nucleo-cytoplasmic
translocation of HDAC9 plays a critical role in activity-dependent
thalamocortical axon branching (Alchini et al., 2017), showing
that a cytoplasmic localization of HDAC5 promotes neurite
growth. Immunohistochemical staining of the adult mouse SN
confirmed a predominantly cytoplasmic localization for HDAC5
and HDAC9, suggesting that this may create a permissive
environment for dopaminergic axon maintenance in adulthood.
However, this will require further investigation.
In this study, we also examined potential mechanisms by
which inhibition of HDAC5 and HDAC9 may promote neurite
growth. A previous study using unbiased ChIP-seq analysis of
HDAC5 genomic binding sites revealed an association between
HDAC5 and the BMP2 promoter (Taniguchi et al., 2017). BMP2
has been proposed as a neuroprotective factor for the treatment of
PD (O’Keeffe et al., 2017; Goulding et al., 2019). The association
reported in the Taniguchi study suggests that HDAC5 may
regulate BMP2 expression. In agreement with this, we found
that pharmacological inhibition of class-IIa HDACs, using the
selective classIIa HDAC inhibitor MC1568, led to a significant
increase in BMP2 and SMAD1 expression in SH-SY5Y cells. More
recently, BMP2 and BMPRs have been found to be co-expressed
with multiple markers of dopaminergic neurons in the adult
human SN (Goulding et al., 2019), suggesting that BMPs may
contribute to the maintenance of these neurons in adulthood.
Supporting evidence for this comes from a study of BMPR2
dominant negative (BMPR2DN) mice (Chou et al., 2008). Adult
BMPR2DN mice displayed a 20% loss in the number of mDA
neuron neurons, and a ∼90% loss of striatal innervation (Chou
et al., 2008). The expression of HDAC5 and HDAC9 in adult
dopaminergic neurons suggests that HDAC5 and HDAC9 may
have potential as new therapeutic targets for stimulating BMP2
and SMAD1 expression in vivo in the adult brain.
Since HDAC inhibition resulted in increased BMP2
expression in SH-SY5Y cells, and activated Smad dependent gene
transcription, we hypothesized that the canonical BMP-Smad
pathway may underlie the neurite growth-promoting effects of
HDAC5 and HDAC9 inhibition. In support of this, BMP2 has
previously been shown to promote neurite growth in both SH-
SY5Y cells (Hegarty et al., 2013) and cultured rat dopaminergic
neurons (Hegarty et al., 2014) through the canonical BMPR-
Smad pathway. BMPs have also been shown to be important in
the regulation of dopaminergic development in vivo (Jovanovic
et al., 2018), and knockout of a negative regulator of the
BMP-Smad pathway leads to striatal hyperinnervation during
development (Hegarty et al., 2017). In support of a role for
regulation of BMP-Smad pathway by HDAC5 and HDAC9,
we found that inhibition of the BMP-Smad pathway using
either of three complementary strategies - treatment with the
BMPR1 inhibitor dorsomorphin, overexpression of Smad4dn or
overexpression of the inhibitory Smad7 - prevented the neurite
growth-promoting effects of HDAC siRNAs. In support of a
link between BMP and HDACs, previous work has also shown
that HDACs act to suppress BMP-promoted astrogliogenesis in
the embryonic forebrain (Scholl et al., 2012) and that HDAC-
dependent transcriptional repression of Bmp-7 potentiates
TGF-β mediated renal fibrosis (Manson et al., 2014). Collectively,
these data suggest that HDAC5 and HDAC9 may act as negative
regulators of the BMP-Smad pathway and that they act to limit
the extent of neurite growth.
Finally, we found that HDAC5 and HDAC9 siRNA could
promote neurite growth in SH-SY5Y cells overexpressing either
wild-type or A53T-α-synuclein. α-synuclein has previously been
shown to bind directly to histones and to reduce the level
of acetylated histone 3 in cultured cells (Kontopoulos et al.,
2006; Paiva et al., 2017). Moreover a recent transcriptome
analysis of Lund Human Mesencephalic (LUHMES) cells showed
that treatment with the pan-HDAC inhibitor sodium butyrate
rescued α-synuclein-induced transcriptional changes (Paiva
et al., 2017). The authors proposed that future studies will
be crucial to define novel possible targets for intervention in
PD. Here we suggest that HDAC5 and HDAC9 may be such
targets. Furthermore, since inhibition of HDAC5 and HDAC9
upregulated BMP2 expression in this study, it is worth noting
that BMP2 can promote neurite growth in both SH-SY5Y cells
and in cultured rat midbrain neurons overexpressing α-synuclein
(Goulding et al., 2019).
In agreement with these findings, we also report that class-
IIa HDI can promote neurite growth of cultured DA neurons
and protect them against MPP+-induced degeneration. Pan-
HDAC inhibitors such as sodium butyrate, valproic acid and
SAHA have been shown to protect cells from apoptosis and
mitochondrial fragmentation induced by MPP+ treatment (Kidd
and Schneider, 2010). Given the lack of specificity of these
HDIs, our data suggest that HDAC5 and HDAC9 inhibition
may, at least in part, underlie the beneficial effects of HDAC
inhibition in DA neurons. These findings suggest that HDAC5
and HDAC9 inhibition may have therapeutic potential to protect
against α-synuclein-induced degeneration. In agreement with
this proposal of targeting individual HDACs, one study has
shown that pharmacological inhibitors of, or siRNA against,
the Class-III HDAC SIRT2 rescued α-synuclein-induced toxicity
and modified inclusion morphology in a cellular model of
PD (Outeiro et al., 2007). In contrast however, a recent study
has shown that the Class III HDI nicotinamide exacerbated
neurodegeneration in the lactacystin rat model of PD (Harrison
et al., 2019). This highlights the importance of targeting specific
HDACs in any therapeutic application.
In summary, we show that inhibition of HDAC5 and HDAC9
promotes neurite growth through regulation of the BMP-
Smad signaling pathway. These findings suggest that HDAC5
and HDAC9 may be novel therapeutic targets worthy of
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further exploration in strategies aimed at axonal protection
against α-synuclein-induced damage in iPSC-derived human DA
neurons and in vivo models of PD.
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